Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1 8Phase 3 2Phase 1/2 2Phase EARLY_PHASE1 1Phase 2/3 1

Status

Terminated 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2CNS 1

Conditions

Glioblastoma 2Breast Neoplasms 2Brain Neoplasms 2Tongue Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Salivary Gland Neoplasms 1Gliosarcoma 1Colorectal Neoplasms 1

Interventions

Trastuzumab 62Paclitaxel 57Cyclophosphamide 44pembrolizumab 34Fulvestrant 34Capecitabine 29Carboplatin 26Docetaxel 23Letrozole 22Doxorubicin 19palbociclib 16abemaciclib 16pertuzumab 15durvalumab 14Filgrastim 13Everolimus 13ribociclib 12Lapatinib 12Gemcitabine 12exemestane 11eribulin 11Vinorelbine 11Albumin-Bound Paclitaxel 11Bevacizumab 10trastuzumab deruxtecan 9neratinib 9fludarabine 9Taxes 9Radiotherapy 9Peripheral Blood Stem Cell Transplantation 9

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Breast Neoplasms × NVP-BKM120 × Clear all
NCT01589861 2026-04-21

PIKHER2

Institut Paoli-Calmettes

Phase 1/2 Terminated
24 enrolled
Breast

Breast Neoplasms

NCT01132664 2016-08-17

Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer

Novartis

Phase 1/2 Terminated
72 enrolled 15 charts
BreastCNS

Brain Neoplasms, Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡